Allergan PLC. (NYSE:AGN) Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Allergan PLC. (AGN) opened at $168.00 on Thursday. Allergan PLC. has a 52 week low of $160.07 and a 52 week high of $256.80. The company has a market cap of $54,636.75, a PE ratio of 10.65, a P/E/G ratio of 1.10 and a beta of 1.11. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the business earned $3.32 EPS. Allergan’s quarterly revenue was up 11.4% on a year-over-year basis. equities analysts forecast that Allergan PLC. will post 16.28 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. The ex-dividend date is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.67%. Allergan’s dividend payout ratio (DPR) is currently -12.44%.
Large investors have recently made changes to their positions in the business. Howard Hughes Medical Institute acquired a new position in shares of Allergan during the 2nd quarter worth approximately $103,000. Cable Hill Partners LLC grew its position in shares of Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its position in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Jacobi Capital Management LLC grew its position in shares of Allergan by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares in the last quarter. Finally, Massey Quick & Co. LLC grew its position in shares of Allergan by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares in the last quarter. Hedge funds and other institutional investors own 81.34% of the company’s stock.
AGN has been the topic of several analyst reports. Citigroup reissued a “buy” rating and set a $280.00 price target on shares of Allergan in a research report on Wednesday, September 20th. Deutsche Bank set a $251.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Piper Jaffray Companies set a $227.00 price target on shares of Allergan and gave the stock a “hold” rating in a research report on Friday, October 6th. J P Morgan Chase & Co reissued a “buy” rating and set a $275.00 price target on shares of Allergan in a research report on Monday, October 16th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $285.00 price target on shares of Allergan in a research report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. Allergan has an average rating of “Buy” and a consensus target price of $241.56.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.